Earnings Review and Free Research Report: Zoetis’ Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance

Research Desk Line-up: Galectin Therapeutics Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Zoetis Inc. (NYSE: ZTS), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ZTS, following the Company's announcement of its financial results on August 08, 2017, for the second quarter of FY17. The Company reported y-o-y increase in revenues by 5%, net income by 10.3% and earnings by 11.1%. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Drugs - Generic industry. Pro-TD has currently selected Galectin Therapeutics, Inc. (NASDAQ: GALT) for due-diligence and potential coverage as the Company reported on August 14, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on Galectin Therapeutics when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ZTS; also brushing on GALT. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=ZTS

http://protraderdaily.com/optin/?symbol=GALT

Earnings Reviewed

Zoetis reported revenues of $1.27 billion for the second quarter of FY17 compared to $1.21 billion for the second quarter of FY16, registering a growth of 5% y-o-y. The Company reported net income of $247 million for Q2 FY17 compared to $224 million for the same quarter in the last fiscal year; reporting an increase by 10.3% y-o-y.

The earnings per diluted share (EPS) announced by Zoetis were $0.50 for Q2 FY17 versus $0.45 announced in Q2 FY16; a rise of 11.1% y-o-y. The non-GAAP adjusted diluted EPS was at $0.53 for Q2 FY17.

The adjusted diluted EPS and revenues reported by the Company beat analysts' estimates of $0.52 per share and revenues of $1.25 billion.

Segment Information

The revenues generated by the livestock business of Zoetis was $689 million in Q2 FY17 compared to $673 million in the corresponding quarter of the last fiscal year; a growth of 2% y-o-y in total and operational growth of 3% y-o-y. In the US, the Company generated revenues of $269 million from this segment in second quarter of FY17 versus $262 million in Q2 FY16; a rise of 3% y-o-y in total and in operational growth as well. The international livestock's revenues for the Company was $420 million in Q2 FY17 compared to $411 million in same quarter of the last fiscal year; a growth of 2% in total and operational growth of 3% y-o-y.

From its companion animal business, Zoetis generated $568 million in Q2 FY17 versus $523 million in Q2 FY16; a growth of 9% y-o-y in total and operational growth of 10% y-o-y. In the US, this segment generated revenues of $354 million in the second quarter of FY17 compared to $332 million in Q2 FY16; a rise of 7% y-o-y in total and operational growth of 7% y-o-y. The Company's international companion animal's revenues were $214 million in Q2 FY17 compared to $191 million in same quarter of the last fiscal year; a rise of 12% y-o-y in total and operational growth of 15% y-o-y.

Contract manufacturing generated $12 million in revenues in Q2 FY17 and was flat compared to same period last quarter.

Cash Matters

Zoetis generated $299 million in net cash from its operating activities in H1 2017 compared to $188million in H1 2016. The Company expended $88 million in investing activities in the first half of 2017 compared to $31 million in the same period last year.

Net cash used in financing activities by Zoetis was $240 million in H12017 versus $651 million in H1 2016. The cash and cash equivalents at end of H1 2017 remaining with Zoetis was $705 million compared to $658 at the end of the same period last year.

In H1 2017, the Company declared but did not pay dividends worth $52 million and in the same period last year it had announced dividends of $47 million but had not paid yet.

Outlook

The guidance of the full year of 2017 was updated by Zoetis and the Company now expects full year revenue to be between $5.150 billion to $5.250 billion; diluted EPS to be in the range of $2.12 to $2.21 per share; and adjusted diluted EPS to be in the band of $2.30 to $2.37 per share.

Stock Performance

At the closing bell, on Friday, August 25, 2017, Zoetis' stock was slightly down 0.10%, ending the trading session at $61.33. A total volume of 1.97 million shares have exchanged hands. The Company's stock price surged 13.93% in the past six months and 21.52% in the previous twelve months. Moreover, the stock rallied 14.57% since the start of the year. The stock is trading at a PE ratio of 34.63 and has a dividend yield of 0.68%. The stock currently has a market cap of $30.03 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily